Best Peptides for Women Over 40: Evidence, Uses & 2026 Status

The peptides most often discussed for women over 40 are sermorelin (growth-hormone axis), GHK-Cu (skin), PT-141/bremelanotide (sexual desire), kisspeptin (reproductive signaling), BPC-157 (joints and soft tissue), and Khavinson bioregulators such as Epitalon. Only one of them, bremelanotide (Vyleesi), is FDA-approved, and only for premenopausal women with hypoactive sexual desire disorder. The rest have human evidence that ranges from small trials to essentially none. None of these peptides treats hot flashes, prevents menopausal bone loss, or replaces menopausal hormone therapy.

This guide is the companion to our peptides for men over 40. It summarizes the physiology, then reviews each peptide's evidence and regulatory status as of October 2026.

Educational content for licensed healthcare professionals. Not medical advice; dosing and treatment decisions belong to the prescribing clinician.

Evidence and Status at a Glance

What Changes After 40: A Brief Physiology Refresher

The menopausal transition is defined by changes in the menstrual cycle and in hormone levels, not by age alone. The STRAW+10 staging system describes a late reproductive stage, an early and late menopausal transition marked by increasing cycle variability and then skipped cycles, and postmenopause, which begins at the final menstrual period [1]. During the transition, FSH rises and becomes variable, estradiol fluctuates and eventually falls, and ovarian reserve markers decline [1].

Common clinical consequences include vasomotor symptoms, sleep disruption, genitourinary syndrome of menopause, changes in sexual desire, loss of bone density, shifts in body composition toward central fat, and skin changes as collagen declines. Separately, the growth hormone/IGF-1 axis declines with age in both sexes.

That is the context in which patients ask about peptides.

Peptides Are Not a Substitute for Menopausal Hormone Therapy

The Menopause Society's (formerly NAMS) 2022 position statement states that hormone therapy "remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture." For women younger than 60 or within 10 years of menopause onset who have no contraindications, it calls the benefit-risk ratio favorable [2].

No peptide in this article has comparable evidence for hot flashes, night sweats, vaginal atrophy, or fracture prevention. Peptides may be discussed alongside indicated therapy, but they should not be presented as replacing it. Our article on peptide and hormone therapy for menopause symptoms covers the full menu of options.

1. PT-141 (Bremelanotide): Sexual Desire

What it is. Bremelanotide is a melanocortin-receptor agonist. It is the only peptide on this list approved by the FDA, as Vyleesi, for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).

Evidence. Two identical phase 3 randomized, double-blind, placebo-controlled trials (RECONNECT) enrolled 1,267 premenopausal women with HSDD, with a mean age of 39. Bremelanotide produced statistically significant improvements in sexual desire and reductions in desire-related distress compared with placebo [3]. Nausea, flushing and headache occurred in 10% or more of participants [3].

The over-40 caveat. The approval and the pivotal trials cover premenopausal women. Use in postmenopausal women is off-label and has not been established by those trials. For more, see PT-141 for women.

Evidence level: randomized phase 3 trials (premenopausal).

2. Sermorelin: The Growth Hormone Axis

What it is. Sermorelin is GHRH(1-29), the active fragment of growth-hormone-releasing hormone. It stimulates the pituitary to release its own growth hormone rather than supplying GH directly.

Evidence in women. The most relevant study is a small 1997 randomized, placebo-controlled trial in 10 women and 9 men aged 55–71, using a closely related GHRH(1-29) analog. Treatment raised nocturnal GH and IGF-1 in both sexes and increased skin thickness in both. However, gains in lean body mass, insulin sensitivity, well-being and libido appeared in men but not in women [4]. The authors concluded that the anabolic effects favored men.

That sex difference is worth discussing with female patients who expect body-composition results. See sermorelin side effects for the safety profile.

Evidence level: small randomized trial; limited female-specific data.

3. GHK-Cu: Skin and Tissue Remodeling

What it is. GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-histidyl-lysine). It is used in topical cosmetics and studied for tissue repair.

Evidence. A 2018 review by GHK-Cu's discoverer summarizes laboratory and animal findings: increased collagen, elastin and glycosaminoglycan synthesis, support of dermal fibroblast function, and effects on many gene-expression pathways [5]. That is relevant to the collagen decline women notice after menopause. Most of the evidence is in vitro, animal, or from cosmetic studies, and the review is not a systematic appraisal.

Status and safety. GHK-Cu is scheduled for the second PCAC meeting expected before the end of February 2027. See GHK-Cu FDA status.

Evidence level: largely in vitro and animal; cosmetic human data.

4. Kisspeptin: Reproductive Signaling and Desire

What it is. Kisspeptin is the hypothalamic peptide upstream of GnRH and the key activator of the reproductive hormone axis.

Evidence. In a randomized, double-blind, placebo-controlled crossover study, 32 premenopausal women with HSDD completed both kisspeptin and placebo sessions. Kisspeptin changed brain activity in response to erotic and facial-attraction stimuli on functional MRI, and some of those changes correlated with sexual distress and aversion scores. It was well tolerated [6]. This is a mechanistic brain-imaging study. It did not test whether kisspeptin improves sexual function over time, and it did not include peri- or postmenopausal women.

Status. Kisspeptin is investigational and not FDA-approved. FDA lists kisspeptin-10 in 503A Category 2 (significant safety risks) on its category list updated May 14, 2026; see the FDA Peptide Status Tracker.

Evidence level: small randomized mechanistic trial (premenopausal).

5. BPC-157: Joints and Soft Tissue

What it is. BPC-157 is a 15-amino-acid peptide derived from a gastric protein and studied for tendon, ligament and muscle healing.

Evidence. A 2025 systematic review found 36 studies, 35 of them preclinical. Animal models showed improved healing in muscle, tendon, ligament and bone, and no clinical safety data were found [7]. A 2026 systematic review limited to human studies found three studies with 30 participants in total, rated the certainty of evidence "very low", and concluded that BPC-157 should not be used clinically outside regulated trials [8].

Status. At the July 2026 PCAC meeting the committee voted 8–6 (1 abstention) to recommend adding BPC-157 to the 503A Bulks List, against FDA staff's recommendation. It is not on the list until FDA rulemaking is complete. See BPC-157 side effects.

Evidence level: preclinical; very low-certainty human data.

6. Bioregulators: Epitalon, Testagen and Their Siblings

Khavinson "peptide bioregulators" are short peptides linked by their developers to specific organs. Epitalon is the one most discussed for women. An independent 2026 review concluded it is "biologically active but clinically unproven": human evidence is limited to small biomarker studies, and long-term safety data are inadequate [9]. At the July 2026 PCAC meeting, the committee voted 7–4 (1 abstention) to recommend Epitalon for the Bulks List; rulemaking is pending.

Testagen is sometimes discussed for women too. Our article on peptide bioregulators and women's hormone health covers that question specifically. Most evidence for bioregulators comes from a single Russian research group, in small studies, with limited independent replication.

Evidence level: animal and small human biomarker studies.

How to Frame Peptides for Patients Over 40

• Start with the indication, not the peptide. Vasomotor symptoms, genitourinary syndrome of menopause and bone protection have established therapies [2]. Low desire has one approved peptide, for premenopausal women.
• State the evidence level plainly. Several peptides patients ask about have mostly animal data.
• Check regulatory status first. Compounded access depends on the 503A Bulks List and FDA's interim categories, which are in flux.
• Individualize. Dosing and treatment decisions belong to the prescribing clinician.

Newtropin's women's health services page explains how providers work with our partner pharmacies. For hormone-focused options, see top peptides for women's hormonal balance.

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with licensed 503A partner pharmacies covering all 50 states and D.C.; prescribers can start at For Providers.

Frequently Asked Questions

What are the best peptides for women over 40?

The most discussed are PT-141 (bremelanotide), sermorelin, GHK-Cu, kisspeptin, BPC-157 and Epitalon. Only bremelanotide is FDA-approved, as Vyleesi for premenopausal women with HSDD. The others range from small human trials to mostly animal data, so the best choice depends on the indication and the evidence.

Can peptides replace hormone therapy in menopause?

No. Menopausal hormone therapy remains the most effective treatment for hot flashes and genitourinary symptoms and prevents bone loss and fracture. No peptide has comparable evidence for those outcomes.

Is PT-141 approved for postmenopausal women?

No. Vyleesi (bremelanotide) is FDA-approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its phase 3 trials enrolled premenopausal women, so use after menopause is off-label.

Does sermorelin work as well for women as for men?

In a small randomized trial of adults aged 55–71, a GHRH(1-29) analog raised GH and IGF-1 and increased skin thickness in both sexes. Gains in lean mass, insulin sensitivity, well-being and libido appeared only in men.

Are peptides for women over 40 FDA-approved?

Only bremelanotide (Vyleesi) is FDA-approved, and only for premenopausal HSDD. Sermorelin was previously approved as Geref but that product was discontinued. BPC-157 and Epitalon received advisory PCAC recommendations in July 2026 with rulemaking pending, and GHK-Cu is scheduled for a 2027 PCAC meeting.

Is GHK-Cu good for skin after menopause?

Laboratory and animal studies show GHK-Cu increases collagen and elastin production and supports fibroblast function, which is relevant to post-menopausal skin changes. Most evidence is preclinical or cosmetic, not from randomized trials in menopausal women.

References

1. Harlow SD, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159-1168. PubMed
2. The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. PubMed
3. Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. PubMed
4. Khorram O, et al. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. PubMed
5. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PubMed
6. Thurston L, et al. Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2022;5(10):e2236131. PubMed
7. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. PubMed
8. Poolton JT, et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026;92(3). PubMed
9. Jain A, et al. Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence. Int J Mol Sci. 2026;27(19):8922. PubMed